Serum β2-Microglobulin is Associated with Mortality in Hospitalized Patients with Exacerbated Chronic Obstructive Pulmonary Disease

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Chapter 1: definition and overview. 2019; 4 Available from: http://goldcopd.org. Accessed 65, 2019.
   Google Scholar
• World Health Organization. World Health Organization (WHO) website. Available from: www.who.int/respiratory/copd/burden/en/. Accessed 65, 2019.
   Google Scholar
• WangC, XuJ, YangL, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China pulmonary health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-929650248
   PubMed Web of Science ®Google Scholar
• SeemungalTA, DonaldsonGC, PaulEA, BestallJC, JeffriesDJ, WedzichaJA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–1422. doi:10.1164/ajrccm.157.5.97090329603117
   PubMed Web of Science ®Google Scholar
• OzkayaS, FindikS, AticiAG. The costs of hospitalization in patients with acute exacerbation of chronic obstructive pulmonary disease. Clinicoecon Outcomes Res. 2011;3:15–18. doi:10.2147/CEOR21935328
   PubMedGoogle Scholar
• WedzichaJA, SeemungalTA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796. doi:10.1016/S0140-6736(07)61382-817765528
   PubMed Web of Science ®Google Scholar
• SinganayagamA, SchembriS, ChalmersJD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10(2):81–89. doi:10.1513/AnnalsATS.201208-043OC23607835
   PubMedGoogle Scholar
• GodtfredsenNS, JorgensenDV, MarsaaK, et al. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD. Respir Res. 2018;19(1):97. doi:10.1186/s12931-018-0803-229783959
   PubMed Web of Science ®Google Scholar
• FruchterO, YiglaM, KramerMR. D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation. Am J Med Sci. 2015;349(1):29–35. doi:10.1097/MAJ.000000000000033225233043
   PubMed Web of Science ®Google Scholar
• ChangCL, RobinsonSC, MillsGD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66(9):764–768. doi:10.1136/thx.2010.15533321474497
   PubMed Web of Science ®Google Scholar
• YaoC, LiuX, TangZ. Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2285–2290. doi:10.2147/COPD.S14176028814856
   PubMed Web of Science ®Google Scholar
• SteerJ, GibsonJ, BourkeSC. The DECAF score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax. 2012;67(11):970–976. doi:10.1136/thoraxjnl-2012-20210322895999
   PubMed Web of Science ®Google Scholar
• EchevarriaC, SteerJ, Heslop-MarshallK, et al. Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD. Thorax. 2016;71(2):133–140. doi:10.1136/thoraxjnl-2015-20777526769015
   PubMed Web of Science ®Google Scholar
• ZijlstraM, BixM, SimisterNE, LoringJM, RauletDH, BetaJR. 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature. 1990;344(6268):742–746. doi:10.1038/344742a02139497
   PubMed Web of Science ®Google Scholar
• ArgyropoulosCP, ChenSS, NgYH, et al. Rediscovering beta-2 microglobulin as a biomarker across the spectrum of kidney diseases. Front Med. 2017;4:73. doi:10.3389/fmed.2017.00073
   PubMed Web of Science ®Google Scholar
• VibertiGC, KeenH, BetaMD. 2-microglobulinaemia: a sensitive index of diminishing renal function in diabetics. Br Med J (Clin Res Ed). 1981;282(6258):95–98. doi:10.1136/bmj.282.6258.95
   PubMed Web of Science ®Google Scholar
• InkerLA, TighiouartH, CoreshJ, et al. GFR estimation using beta-trace protein and beta2-microglobulin in CKD. Am J Kidney Dis. 2016;67(1):40–48. doi:10.1053/j.ajkd.2015.07.02526362696
   PubMed Web of Science ®Google Scholar
• GaoN, WangY, ZhengCM, et al. Beta2-microglobulin participates in development of lung emphysema by inducing lung epithelial cell senescence. Am J Physiol Lung Cell Mol Physiol. 2017;312(5):L669–L677. doi:10.1152/ajplung.00516.201628213472
   PubMed Web of Science ®Google Scholar
• MullerovaH, MaselliDJ, LocantoreN, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest. 2015;147(4):999–1007. doi:10.1378/chest.14-065525356881
   PubMed Web of Science ®Google Scholar
• NavaS, HillN. Non-invasive ventilation in acute respiratory failure. Lancet. 2009;374(9685):250–259. doi:10.1016/S0140-6736(09)60496-719616722
   PubMed Web of Science ®Google Scholar
• Martin-GonzalezF, Gonzalez-RobledoJ, Sanchez-HernandezF, Moreno-GarciaMN, Barreda-MelladoI. Effectiveness and predictors of failure of noninvasive mechanical ventilation in acute respiratory failure. Med Intensiva. 2016;40(1):9–17. doi:10.1016/j.medin.2015.01.00725759114
   PubMed Web of Science ®Google Scholar
• CharlsonME, PompeiP, AlesKL, MacKenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• QuanH, LiB, CourisCM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi:10.1093/aje/kwq43321330339
   PubMed Web of Science ®Google Scholar
• MillerJ, EdwardsLD, AgustiA, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376–1384. doi:10.1016/j.rmed.2013.05.00123791463
   PubMed Web of Science ®Google Scholar
• BarnesPJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16–27. doi:10.1016/j.jaci.2016.05.01127373322
   PubMed Web of Science ®Google Scholar
• HurstJR, DonaldsonGC, PereraWR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(8):867–874. doi:10.1164/rccm.200604-506OC16799074
   PubMed Web of Science ®Google Scholar
• AygunduzM, BavbekN, OzturkM, KaftanO, KosarA, KirazliS. Serum beta 2-microglobulin reflects disease activity in behcet’s disease. Rheumatol Int. 2002;22(1):5–8. doi:10.1007/s00296-002-0180-412120912
   PubMed Web of Science ®Google Scholar
• YilmazB, KokluS, YukselO, ArslanS. Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease. World J Gastroenterol. 2014;20(31):10916–10920. doi:10.3748/wjg.v20.i31.1091625152594
   PubMed Web of Science ®Google Scholar
• KimHA, JeonJY, YoonJM, SuhCH. Beta 2-microglobulin can be a disease activity marker in systemic lupus erythematosus. Am J Med Sci. 2010;339(4):337–340. doi:10.1097/MAJ.0b013e3181d26dfb20186038
   PubMed Web of Science ®Google Scholar
• WangHJ, SiQJ, ShiY, GuoY, LiY, WangYT. The prognostic values of beta-2 microglobulin for risks of cardiovascular events and mortality in the elderly patients with isolated systolic hypertension. J Res Med Sci. 2018;23(1):82. doi:10.4103/jrms.JRMS_135_1730294350
   PubMed Web of Science ®Google Scholar
• MockelM, MullerR, SearleJ, et al. Usefulness of beta2-microglobulin as a predictor of all-cause and nonculprit lesion-related cardiovascular events in acute coronary syndromes (from the PROSPECT study). Am J Cardiol. 2015;116(7):1034–1040. doi:10.1016/j.amjcard.2015.07.01726254706
   PubMed Web of Science ®Google Scholar
• EvrinPE, WibellL. The serum levels and urinary excretion of 2 -microglobulin in apparently healthy subjects. Scand J Clin Lab Invest. 1972;29(1):69–74. doi:10.3109/003655172090810575014998
   PubMed Web of Science ®Google Scholar
• StangaZ, NockS, Medina-EscobarP, NydeggerUE, RischM, RischL. Factors other than the glomerular filtration rate that determine the serum beta-2-microglobulin level. PLoS One. 2013;8(8):e72073. doi:10.1371/journal.pone.007207323991042
   PubMed Web of Science ®Google Scholar
• ShinkaiS, ChavesPH, FujiwaraY, et al. Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein. Arch Intern Med. 2008;168(2):200–206. doi:10.1001/archinternmed.2007.6418227369
   PubMedGoogle Scholar
• KawaiK, KawashimaS, MiyazakiT, et al. Serum beta2-microglobulin concentration as a novel marker to distinguish levels of risk in acute heart failure patients. J Cardiol. 2010;55(1):99–107. doi:10.1016/j.jjcc.2009.10.00320122555
   PubMed Web of Science ®Google Scholar
• FosterMC, CoreshJ, HsuCY, et al. Serum beta-trace protein and beta2-microglobulin as predictors of ESRD, mortality, and cardiovascular disease in adults with CKD in the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2016;68(1):68–76. doi:10.1053/j.ajkd.2016.01.01526948990
   PubMed Web of Science ®Google Scholar
• MacIntyreN, HuangYC. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):530–535. doi:10.1513/pats.200707-088ET18453367
   PubMedGoogle Scholar
• PavasiniR, TavazziG, BiscagliaS, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis. Chron Respir Dis. 2017;14(2):117–126. doi:10.1177/147997231667439327956645
   PubMed Web of Science ®Google Scholar
• LeuzziG, GaleoneC, TavernaF, SuatoniP, MorelliD, PastorinoU. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2017;26(143):160070. doi:10.1183/16000617.0070-201628143876
   PubMed Web of Science ®Google Scholar
• FermontJM, MasconiKL, JensenMT, et al. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis. Thorax. 2019;74(5):439–446. doi:10.1136/thoraxjnl-2018-21185530617161
   PubMed Web of Science ®Google Scholar
• SteerJ, NormanEM, AfolabiOA, GibsonGJ, BourkeSC. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax. 2012;67(2):117–121. doi:10.1136/thoraxjnl-2011-20033221896712
   PubMed Web of Science ®Google Scholar